Results of a combination treatment with natamycin and butylscopolamine in cases of intestinal Candida colonization.
The findings described show that Candida species can be found in the feces of approximately half a population of nonselected test persons and in the mouths of approximately a third. Intestinal Candida colonization was found in most of these persons after one feces examination, and in practically all of them after a second examination. 10 d of therapy with 400 mg natamycin per day in sugar-coated tablet form and 40 mg natamycin in the form of tablets for sucking produced a negative fungus test for the feces in only 20% of the cases. Although a combination of this therapy with 3 x 10 mg butylscopolamine per day improved short-term results significantly, the long-term results were hardly influenced at all. Typifying results according to the Warnock method showed that we are dealing with recurrences in practically all cases and not with new infections. Minimal inhibition concentrations (MIC) of natamycin showed no marked changes as a consequence of the natamycin treatment.
Gehring
W
W
Hautklinik am Klinikum der Stadt Karlsruhe, Germany FR.
Späte
W
W
Gehse
M
M
Gloor
M
M
Braun
K J
KJ
D000328:Adult; D002086:Butylscopolammonium Bromide / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy*; D002353:Carrier State / Q000188:drug therapy*; D005243:Feces / Q000382:microbiology; D005260:Female; D006801:Humans; D007410:Intestinal Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009055:Mouth / Q000382:microbiology; D010866:Natamycin / Q000627:therapeutic use*; D012602:Scopolamine Derivatives / Q000627:therapeutic use*
D012602:Scopolamine Derivatives; D002086:Butylscopolammonium Bromide; D010866:Natamycin